{"id":23846,"date":"2025-05-15T13:30:55","date_gmt":"2025-05-15T06:30:55","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23846"},"modified":"2025-05-15T13:30:55","modified_gmt":"2025-05-15T06:30:55","slug":"steerlife-redefines-potent-drug-development-with-clean-green-continuous-processing","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23846","title":{"rendered":"STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development<\/i> <\/p>\n

BENGALURU, India<\/span>, May 15, 2025<\/span> \/PRNewswire\/ —\u00a0STEERLife<\/i>, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.<\/p>\n

At the core of this advancement is\u00a0STEERLife<\/i>‘s proprietary\u00a0solvent-free melt fusion technology<\/b>, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.<\/p>\n

As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEERLife<\/i>\u00a0provides comprehensive development capabilities for complex and potent drugs – including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation.<\/p>\n

“Potent drug development demands more than just compliance; it requires control, care, and innovation,”\u00a0said Indu Bhushan, CEO & Director at STEERLife<\/i><\/b>. “Our continuous, solvent-free platform brings all of that together – enabling faster, cleaner and more scalable development for the world’s most demanding therapies.”<\/p>\n

STEERLife<\/i>\u00a0has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of\u00a0ERLEADA\u00ae (Apalutamide), XTANDI\u00ae (Enzalutamide), VENCLEXTA\u00ae (Venetoclax), and LYNPARZA\u00ae (Olaparib),<\/b>\u00a0reflecting the company’s ability to take on complex, high-barrier drug programs with confidence.<\/p>\n

Working in tandem with partner facilities, STEERLife<\/i>\u00a0is strategically positioned to serve leading pharmaceutical markets across the\u00a0United States, Europe, Latin America, Russia, MENA and Southeast Asia.<\/b><\/p>\n

As a company that pioneered the shift from batch to seamless continuous processing in India, STEERLife\u00a0<\/i>continues to lead the evolution of pharmaceutical manufacturing – empowering clients worldwide to shorten development timelines, raise quality benchmarks and unlock next-gen drug delivery.<\/p>\n

About STEERLife<\/i><\/b> <\/p>\n

STEERLife<\/i><\/b>, a division of STEER World, is a pioneering life sciences company transforming how pharmaceuticals are developed, manufactured, and consumed. Leveraging cutting-edge continuous processing and proprietary clean & green technologies, STEERLife<\/i> enables faster, greener and more efficient drug development. The company offers a complete spectrum of services to global partners: ranging from formulation and analytical development to technology transfer, regulatory support and commercial-scale manufacturing.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development<\/i> <\/p>\n

BENGALURU, India<\/span>, May 15, 2025<\/span> \/PRNewswire\/ —\u00a0STEERLife<\/i>, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.<\/p>\n

At the core of this advancement is\u00a0STEERLife<\/i>‘s proprietary\u00a0solvent-free melt fusion technology<\/b>, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.<\/p>\n

As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEERLife<\/i>\u00a0provides comprehensive development capabilities for complex and potent drugs – including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation.<\/p>\n

“Potent drug development demands more than just compliance; it requires control, care, and innovation,”\u00a0said Indu Bhushan, CEO & Director at STEERLife<\/i><\/b>. “Our continuous, solvent-free platform brings all of that together – enabling faster, cleaner and more scalable development for the world’s most demanding therapies.”<\/p>\n

STEERLife<\/i>\u00a0has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of\u00a0ERLEADA\u00ae (Apalutamide), XTANDI\u00ae (Enzalutamide), VENCLEXTA\u00ae (Venetoclax), and LYNPARZA\u00ae (Olaparib),<\/b>\u00a0reflecting the company’s ability to take on complex, high-barrier drug programs with confidence.<\/p>\n

Working in tandem with partner facilities, STEERLife<\/i>\u00a0is strategically positioned to serve leading pharmaceutical markets across the\u00a0United States, Europe, Latin America, Russia, MENA and Southeast Asia.<\/b><\/p>\n

As a company that pioneered the shift from batch to seamless continuous processing in India, STEERLife\u00a0<\/i>continues to lead the evolution of pharmaceutical manufacturing – empowering clients worldwide to shorten development timelines, raise quality benchmarks and unlock next-gen drug delivery.<\/p>\n

About STEERLife<\/i><\/b> <\/p>\n

STEERLife<\/i><\/b>, a division of STEER World, is a pioneering life sciences company transforming how pharmaceuticals are developed, manufactured, and consumed. Leveraging cutting-edge continuous processing and proprietary clean & green technologies, STEERLife<\/i> enables faster, greener and more efficient drug development. The company offers a complete spectrum of services to global partners: ranging from formulation and analytical development to technology transfer, regulatory support and commercial-scale manufacturing.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23846"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23846\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}